We performed a two-stage genome-wide association study (GWAS) of antibody titer in 3614 hepatitis B vaccine recipients from Indonesia's Riau Archipelago, leading to the identification of at least three independent signals within the human leukocyte antigen (HLA) complex. These appear to implicate HLA-DR [rs3135363; P 5 6.53 3 10 222 ; odds ratio (OR) 5 1.53, 95% confidence interval (CI) 5 1.35 -1.74]; HLA-DP, previously associated with the risk of chronic hepatitis B infection (rs9277535; P 5 2.91 3 10 212 ; OR 5 0.72, 95% CI 5 0.63 -0.81); and a gene rich HLA Class III interval (rs9267665; P 5 1.24 3 10 217 ; OR 5 2.05, CI 5 1.64 -2.57). The substantial overlap of these variants and those identified by GWAS of chronic hepatitis B infection confirms vaccine response as a model for infection, while suggesting that the vaccine is least effective in those most at risk of lifelong infection, following exposure to the virus.
INTRODUCTION
The hepatitis B virus (HBV) poses a significant public health problem, with nearly a third of the world's population showing serological evidence of resolved or chronic infection. Epidemiological data suggest that 350 million people are chronic carriers, capable of propagating the infection, and contributing to approximately one million deaths from chronic liver diseases and hepatocellular carcinoma each year. Transmission of the virus occurs through exposure to infectious blood or body fluids. In parts of Asia, where the rates of HBV infection are among the highest, transmission is typically vertical from a chronically infected mother to her child during delivery or early infancy. Parenteral infection in adulthood is also an important route of transmission. It is thought that 90% of infections occurring in infancy are chronic, while 10% of infections acquired in late childhood or adulthood are lifelong. A vaccine has been in wide use for nearly 30 years, and-together with other measures, such as the administration of hepatitis B immune globulin to at-risk newborns-has contributed to declining rates of infection worldwide (1) . The standard vaccine course fails to elicit protective antibody levels in nearly 10% of adult recipients, which is similar to the fraction of individuals who are exposed to the live virus and unable to clear the infection or to produce detectable antibodies against it (2) . Twin and other familial studies have estimated a high heritability (77%) for post-vaccination antibody titer (3) . Previous genetic studies of both vaccine induced antibody titer and risk of chronic infection have also uncovered putative or highly significant genetic variants influencing both traits (4 -6) .
With this as motivation, we performed a two-stage genomewide association study (GWAS) of post-vaccination antibody titer to identify variants contributing to vaccine response, and to examine the hypothesis that some of the same variants underlie the risk of chronic infection as well as low post-vaccine antibody titer. Subjects for this study were drawn from a two-dose hepatitis B vaccine efficacy trial conducted on Batam and surrounding Indonesian islands (7) .
RESULTS
In the first stage, following extensive quality-control (QC) filtering, we analyzed 1683 vaccine recipients genotyped on the Illumina HumanHap550 BeadChip for 455 508 autosomal single nucleotide polymorphisms (SNPs) (Supplementary Material, Fig. S1 ). Subjects were grouped into tertiles based on post-vaccination antibody titer, and ordinal logistic regression was used to identify variants associated with the vaccine response. With a genomic control inflation factor (l GC ) of only 1.01, there was little evidence of population stratification, and further adjustments were not made.
From this first stage, we selected SNPs with P , 5.0 × 10 26 in the human leukocyte antigen (HLA) region on chromosome 6 (n ¼ 67), and P , 5.0 × 10 23 for non-HLA SNPs (n ¼ 2312) for replication in a second phase. These 2379 SNPs were submitted for manufacture as an Illumina iSelect BeadChip, of which 596 SNPs (25%) failed in either the design or synthesis stages. After extensive QC filtering, we analyzed genotypes for 1706 SNPs in a second set of 1931 vaccine recipients from the same study. In this second stage, we replicated the conspicuous signal from the HLA region on chromosome 6, and we conducted a joint analysis of the two stages for single SNP associations. All SNPs (n ¼ 47) surpassing Bonferroni-corrected significance thresholds (P ≤ 1.1 × 10 27 ) were located within the HLA region on chromosome 6, with the minimal P-value observed for rs3135363 [single SNP analysis P ¼ 6.53 × 10 222 , odds ratio (OR) ¼ 1.53, 95% confidence interval (CI) ¼ 1.35 -1.74 (Supplementary Material, Table S1)]. Beyond the HLA, the minimal P-value was seen for rs958577 (single SNP analysis P ¼ 5.13 × 10 26 ; OR ¼ 0.66, CI ¼ 0.56-0.78), which is adjacent to the 5 ′ untranslated region (UTR) of ATP2C2 on chromosome 16 (Supplementary Material, Table S1 ).
Although there are extensive tracts of linkage disequilibrium (LD) throughout the HLA region ( Fig. 1 ), we used conditional logistic regression to examine the possibility that 
3894
Human Molecular Genetics, 2011, Vol. 20, No. 19 multiple independent signals across this vast physical expanse were contributing to the observed associations. We used the CI method of Gabriel et al. in HAPLOVIEW (8, 9) to identify 11 independent haplotype blocks in the HLA region, each of which was represented by its most significantly associated SNP (9) . We then applied forward stepwise conditional logistic regression, and identified three independently associated regions across the HLA with P ≤ 1 × 10 27 (Table 1) . Tag SNP rs3135363 (single SNP analysis P ¼ 6.53 × 10 222 ; OR ¼ 1.53, 95% CI ¼ 1.35-1.74) representing haplotype block 9 ( Fig. 1) , encompassing HLA-DR and BTNL2, was the first to emerge from the conditional analysis, and exhibited the strongest evidence of association. Our stepwise analysis next identified tag SNP rs9277535 (single SNP analysis P ¼ 2.91 × 10 212 ; OR ¼ 0.72, 95% CI ¼ 0.63 -0.81) in the 3 ′ UTR of HLA-DPB1. There is a significant breakdown of LD (both D ′ and r 2 ¼ 0) separating the block encompassing HLA-DPA1 and HLA-DPB1, and the rest of the HLA region ( Fig. 1) , which underscores the degree to which variants in these regions are segregating independently. The final signal to emerge from this analysis with genome-wide significance was for tag SNP rs9267665 (single SNP analysis P ¼ 1.24 × 10 217 ; OR ¼ 2.05, CI ¼ 1.64-2.57) representing haplotype block 3 in the HLA class III gene-rich region, where many genes are in close proximity, and are in strong LD. Similar results were also observed in an alternative stepwise conditional logistic regression based on all 47 SNPs attaining genome-wide significance. Here, we started by conditioning the effect of the most significantly associated SNP (rs3135363). Both approaches arrived at the same SNPs representing the independent signals for HLA-DR (rs3135363), and HLA class III (rs9267665). The index SNP for HLA-DP rs9277535 was replaced with rs9277554. Nevertheless, both rs9277535 and rs9277554 are in the same haplotype block (which we have labeled block 11) and are in high LD with each other (D ′ ¼ 1, and r 2 ¼ 0.66), and conditional analyses suggest that they are not independent (Table 1) .
To assess the combined effect of the three loci (rs3135363, rs9277535 and rs9267665), we analyzed genotypes for all three independent loci. The accumulation of alleles that are protective (i.e. the alleles that are more commonly found in vaccine recipients with higher antibody titers) at the three independent loci was demonstrated to have a cumulative effect (P for trend , 1 × 10 226 ; OR 1.47, 95% CI 1.39-1.55). Individuals with an increasing number of protective alleles displayed higher antibody titers than those who inherited fewer such alleles (Fig. 2 ).
DISCUSSION
Consistent with previous studies that have implicated specific HLA-DR alleles (6, 10) , our study demonstrated that the HLA-DR region, tagged by our top SNP rs3135363, was the most significant contributor to antibody response, even after adjusting for the effects of other independent loci (Table 1) . This agrees well with a twin study, showing that the HLA-DR locus alone could account for as much as 40% of the heritability observed for this trait (11) . In addition to vaccine response, this locus may play a role in the ability to hinted at an association with rs11752643, which is in strong LD (r 2 ¼ 0.8, D ′ ¼ 1) with HLA-DR, although it failed to surpass Bonferroni correction in a second-stage replication attempt (5) . The next independent signal to emerge from our conditional analysis was seen at rs9277535, which is located in the 3 ′ UTR of HLA-DPB1. This SNP and a neighboring tag (r 2 ¼ 0.3) rs3077 (single SNP analysis P ¼ 4.47 × 10 28 ; OR ¼ 0.70, 95% CI ¼ 0.61-0.79) were also found to be significantly associated with viral clearance in the aforementioned GWAS of chronic HBV infection in the Japanese and Thai population samples (5) . The final signal to emerge from this analysis with genome-wide significance was for tag SNP rs9267665 (single SNP analysis P ¼ 1.24 × 10 217 ; OR ¼ 2.05, CI ¼ 1.64-2.57) representing haplotype block 3 which encompasses the HLA class III region. This haplotype block is gene rich, and substantial LD among the genes makes it impossible to identify the likely origins of the association signal.
In summary, our study demonstrates a genetic contribution to variability in antibody response following hepatitis B vaccination. All genetic determinants reaching genome-wide significance fall within the HLA region. In-depth analyses of this region revealed the existence of at least three independent signals, and we demonstrate that an increasing number of alleles associated with higher antibody titer had a cumulative effect on post-vaccination antibody titer (P , 1 × 10 226 ).
The apparent concordance of alleles associated with protective effects both for chronic infection and for vaccine response suggests that these related phenotypes share major aspects of their genetic etiologies, and that vaccine response may provide a useful experimental model of a natural infection for genetic and other functional studies of infection. Our findings also raise the possibility that the vaccine is least effective in those who need it most, if many of the same variants that increase risk of a chronic infection are the same variants that increase the odds of vaccine failure, as appears to be the case.
The well-documented function of HLA proteins in presenting foreign peptides to immune cells, as a vital precursor to both the generation of protective B-cell antibodies and T-cellmediated effects, facilitates a ready functional interpretation of these results. The extension of our work, either by imputation (12, 13) or direct typing of the HLA-DP and -DR genes, may identify the actual risk alleles that are ineffective at presenting viral s-antigen peptides from the vaccine, and presumably the live virus as well, to the relevant immune cells. With this information, it should be at least theoretically possible to engineer a second-generation vaccine-containing peptides that could be presented more effectively by a broader set of HLA alleles to T-cell receptors.
MATERIALS AND METHODS

Subjects
Our study population consisted of participants in a two-dose hepatitis B vaccine efficacy trial, residing on Batam and surrounding Indonesian islands near Singapore (7) . This trial initially screened 19 547 individuals over 5 years of age. Subjects who were anti-HBc, anti-HBs or HBsAg positive at entry (n ¼ 4802; 25%) were excluded. A two-dose vaccination schedule (Engerix-B, 20 mg/l recombinant HBsAg; GlaxoSmithKline Biologicals, Belgium) was completed in 13 315 subjects. Post-vaccination antibody titer was measured (Elecsys System, Boehringer/Roche, Germany) 6 months after the final dose in about 5100 subjects from whom serum was available for DNA extraction, forming the study base for our GWAS.
DNA extraction and amplification
DNA extractions and whole genome amplifications were performed on 4576 frozen serum samples by Rubicon Genomics (Ann Arbor, MI, USA) using their proprietary PicoPlex technology (14) .
SNP genotyping and QC filtering
For the initial genome-wide scan, 2057 samples were genotyped for 561 466 SNPs on the fixed content Illumina Human-Hap550 BeadChip (Illumina, CA, USA), and genotypes were called with the ILLUMINUS software (15) , whose genotype clustering and calling algorithm appeared to enhance the accuracy of genotype calls relative to Illumina's BeadStudio software for our whole genome amplified template. Samples were 
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Human Molecular Genetics, 2011, Vol. 20, No. 19 removed based on: call rate , 95% (n ¼ 109), first-degree familial relationships (n ¼ 217), discrepancies with reported gender (n ¼ 31) and discrepancies with previously collected genotype data (n ¼ 17) (6) . After sample exclusions, SNPs were filtered to remove: non-autosomal SNPs (n ¼ 14 008), SNPs with ILLUMINUS perturbation scores , 95% (n ¼ 36 709), call rate , 95% (n ¼ 9849), minor allele frequency (MAF) ,0.005 (n ¼ 42 308) and Hardy -Weinberg equilibrium test of P , 1 × 10 27 (n ¼ 3084). The resulting post-QC data set of 1683 samples genotyped for 455 508 SNPs was then utilized in the association analysis. For the second stage, we submitted 2379 SNPs to Illumina for synthesis on a custom iSelect BeadChip. Of the submitted SNPs, only 1783 (75%) were successfully manufactured. A total of 2156 study samples exhibiting the same distribution of post-vaccination antibody titer were genotyped with this custom iSelect array. Using the same QC criteria, samples were filtered on: call rate , 95% (n ¼ 26), first-degree relationship (n ¼ 283) and discrepancies with previously collected genotype data (n ¼ 3) (6) . After sample exclusions, SNPs were filtered on: Illuminus perturbation score , 95% (n ¼ 41), call rate , 95% (n ¼ 28), MAF , 0.005 (n ¼ 2) and Hardy -Weinberg equilibrium test of ,1 × 10 27 (n ¼ 6). To preserve power, 87 first-degree relatives that were excluded from Stage1, but were found to be unrelated to any Stage2 samples, were included in the Stage2 data set. The final quality-controlled second-stage data set consisted of 1931 samples genotyped for 1706 SNPs.
Statistical analysis
The distribution of antibody titers follows a 'U' shaped distribution ( Supplementary Material, Fig. S2 ) that could not readily be transformed into a normal distribution amenable to conventional statistical analyses. For this reason, we grouped subjects into three groups defined by antibody titer and performed ordinal logistic regression, rather than analyzing as a binary trait. The three groups based on the postvaccination antibody titer were defined as: 0-99.9 IU/l anti-HBs [n ¼ 631 (Stage 1) + 667 (Stage 2) ¼ 1298 subjects], 100-999.9 IU/l anti-HBs [n ¼ 597 (Stage 1) + 653 (Stage 2) ¼ 1250 subjects] and anti-HBs ≥ 1000 IU/l [n ¼ 829 (Stage 1) + 836 (Stage 2) ¼ 1665]. For the ordinal regression, three groups were coded numerically as 0, 1 and 2 to preserve ranking of the levels of antibody titer (2, 16) .
Single SNP tests of association were performed separately in the two stages under a multiplicative genetic model, using ordinal logistic regression across the three vaccine response categories defined above, adjusting for age and sex in STATA version 8. Joint analysis of both stages was performed by combining P-values and Z-scores weighted by the sample size of each stage (17) . We applied a conservative Bonferroni correction to support claims of genome-wide significance [P ≤ 1.1 × 10 27 or (0.05/455 508)].
A LD map of the 11 haplotype blocks defined by the 47 SNPs surpassing genome-wide significance in the HLA region was plotted with the default CI method of Gabriel et al. in Haploview (Fig. 1) (8, 9) . The SNP with the smallest P-value within each block was used as tag to represent each of the 11 haplotype blocks (9) .
To identify potentially independent signals, forward stepwise conditional logistic regression was performed using STATA version 10 with a genome-wide significant threshold of P ¼ 1 × 10 27 to add a variable, and 1.1 × 10 27 to remove a variable from the model. The method begins with a null model, in which the variables were added in an iterative process. Tag SNPs chosen to represent each of the 11 haplotype blocks were the variables. Data from both stages stratified by stage were used, and adjusted for age and sex. An alternative stepwise conditional logistic regression was also performed on all 47 SNPs attaining genome-wide significance, starting with the most significant SNP (rs3135363), and subsequently building each model with the next most significant in rank, using alpha threshold P ¼ 1 × 10 27 to add a variable. Data from both stages stratified by stage were used, and adjusted for age and sex.
The number of copies of alleles associated with higher antibody titer in each individual were added from each of the three independent SNPs (rs3135363, rs9277535 and rs9267665), and was given a total accumulated score. To test for cumulative effects among the independent SNPs, this score was used in the association analysis using ordinal logistic regression across the three vaccine response categories defined above, adjusting for age and sex in STATA version 8.
Software PLINK (18) version 1.05 was used for QC filtering on call rates, sample relatedness, Hardy -Weinberg equilibrium and MAF. Sample relatedness was calculated using pairwise identity by state analysis to find pairs of individuals who are more similar than expected by chance in a random sample. Based on the calculated probabilities, we identified pairs with relationships of an extent expected for monozygous twins, full siblings and parent offspring. In each instance, the sample with the higher call rate was retained in the analysis.
Ordinal logistic regression and the forward stepwise conditional logistic regression were performed using STATA versions 8 and 10, respectively. The R statistical package was used to draw QQ plots, and to calculate the combined P-values across both stages of the study. Haploview was used to plot the negative log of P-values against chromosomal location and LD maps (8, 9) .
